Skip to main content
Erschienen in:

11.08.2023 | Research

N-Terminal Pro-B-Type Natriuretic Peptide as a Marker of Severity of Heart Failure in Children with Congenital Heart Diseases

verfasst von: Ritabrata Roy Chowdhury, Satnam Kaur, Rani Gera

Erschienen in: Pediatric Cardiology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been used as a tool for diagnosis, severity assessment and prognostication of congestive heart failure (CHF) in adults, with specific cut off values for diagnosis and denoting points of intervention. However, there is scarcity of paediatric literature regarding role of NT-proBNP as a marker of heart failure severity and prognostication. So, this study was done to assess the utility of NT-proBNP as a marker of severity of heart failure in children with congenital heart diseases. Single centre, prospective observational study. Children (1 month to 5 years), with congenital heart disease, admitted in the paediatric wards with varying severity of CHF were enrolled. Heart failure severity grading was done according to Laer modification of Ross Classification at the time of presentation to hospital and children were classified as having no/grade I CHF (score: 0–2); mild/grade II CHF (score 3–6); moderate/grade III CHF (score 7–9) or severe/grade IV CHF (score 10–12). NT-proBNP levels were measured within 24 h of admission. Eighty children with congenital heart disease were enrolled in this study. As per modified Ross Classification, 11 had grade I/No heart failure (13.7%), 32 children had grade II/mild heart failure (40%), 36 had grade III/moderate heart failure (45%) and only 1 had grade IV/severe heart failure (1.25%). The median NT-proBNP levels (IQR) in the above mentioned grades of heart failure were found to be 321.11 (211.1–411.78 pg/ml), 750.62 (474.62–995.2 pg/ml), 4159.61 (1440.59–11,857 pg/ml) and 11,320.34 pg/ml, respectively. Seven children (8.75%) expired. Median NT-proBNP value in seven children who died was significantly higher than those who survived [median (IQR): 11,681.01 pg/ml (10,092.72–14,754 pg/ml) vs 839.4 pg/ml (456.67–3288.09 pg/ml), p value < 0.001]. NT-proBNP level of 520.2 pg/ml predicted grade II (mild heart failure) or more severe grades of heart failure with Sensitivity, Specificity, Negative Predictive Value and Positive Predictive Value of 83%, 91%, 57.1% and 98%, respectively. NT-proBNP levels increase progressively with increasing severity of CHF and can be used as a marker of severity of heart failure in children with congenital heart disease presenting with CHF.
Literatur
1.
Zurück zum Zitat van der Linde D, Konings E, Slager M, Witsenburg M, Helbing W, Takkenberg P et al (2011) Birth prevalence of congenital heart disease worldwide. J Am Coll Cardiol 58(21):2241–2247CrossRefPubMed van der Linde D, Konings E, Slager M, Witsenburg M, Helbing W, Takkenberg P et al (2011) Birth prevalence of congenital heart disease worldwide. J Am Coll Cardiol 58(21):2241–2247CrossRefPubMed
2.
Zurück zum Zitat Sahin M, Portakal O, Karagoz T, Hasçelik G, Ozkutlu S (2010) Diagnostic performance of BNP and NT-ProBNP measurements in children with heart failure based on congenital heart defects and cardiomyopathies. Clin Biochem 43:1278–81CrossRefPubMed Sahin M, Portakal O, Karagoz T, Hasçelik G, Ozkutlu S (2010) Diagnostic performance of BNP and NT-ProBNP measurements in children with heart failure based on congenital heart defects and cardiomyopathies. Clin Biochem 43:1278–81CrossRefPubMed
3.
Zurück zum Zitat Mir T, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110(6):76–82CrossRef Mir T, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110(6):76–82CrossRef
4.
Zurück zum Zitat Lin C, Zeng X, Zhang J, Meng X (2014) Determining the optimal cut off values of plasma N-terminal pro–B-type natriuretic peptide levels for the diagnosis of heart failure in children of age up to 14 years. J Card Fail 20(3):168–173CrossRefPubMed Lin C, Zeng X, Zhang J, Meng X (2014) Determining the optimal cut off values of plasma N-terminal pro–B-type natriuretic peptide levels for the diagnosis of heart failure in children of age up to 14 years. J Card Fail 20(3):168–173CrossRefPubMed
5.
Zurück zum Zitat Maher K, Reed H, Cuadrado A, Simsic J, Mahle WT, Deguzman M et al (2008) B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Paediatrics 121(6):1484–1488CrossRef Maher K, Reed H, Cuadrado A, Simsic J, Mahle WT, Deguzman M et al (2008) B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Paediatrics 121(6):1484–1488CrossRef
6.
Zurück zum Zitat Wu YR, Chen SB, Sun K, Huang MR, Zhang YQ, Chen S (2006) Diagnostic value of the currently used criteria and brain natriuretic peptide for diagnosing congestive heart failure in children with congenital heart disease. Zhonghua Er Ke Za Zhi 44:728–732PubMed Wu YR, Chen SB, Sun K, Huang MR, Zhang YQ, Chen S (2006) Diagnostic value of the currently used criteria and brain natriuretic peptide for diagnosing congestive heart failure in children with congenital heart disease. Zhonghua Er Ke Za Zhi 44:728–732PubMed
7.
Zurück zum Zitat Koulouri S, Acherman R, Wong P, Chan L, Lewis A (2004) Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 25(4):341–346CrossRefPubMed Koulouri S, Acherman R, Wong P, Chan L, Lewis A (2004) Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 25(4):341–346CrossRefPubMed
8.
Zurück zum Zitat Cohen S, Springer C, Avital A, Perles Z, Rein A, Argaman Z et al (2005) Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics 115(5):1347–1350CrossRefPubMed Cohen S, Springer C, Avital A, Perles Z, Rein A, Argaman Z et al (2005) Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics 115(5):1347–1350CrossRefPubMed
9.
Zurück zum Zitat Sahingozlu T, Karadas U, Eliacik K, Bakiler A, Ozdemir Karadas N, Kanik M et al (2015) Brain natriuretic peptide: the reason of respiratory distress is heart disease or lung disease? Am J Emerg Med 33(5):697–700CrossRefPubMed Sahingozlu T, Karadas U, Eliacik K, Bakiler A, Ozdemir Karadas N, Kanik M et al (2015) Brain natriuretic peptide: the reason of respiratory distress is heart disease or lung disease? Am J Emerg Med 33(5):697–700CrossRefPubMed
10.
Zurück zum Zitat Hammerer-Lercher A, Geiger R, Mair J, Url C, Tulzer G, Lechner E et al (2006) Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem 52(7):1415–1419CrossRefPubMed Hammerer-Lercher A, Geiger R, Mair J, Url C, Tulzer G, Lechner E et al (2006) Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem 52(7):1415–1419CrossRefPubMed
11.
Zurück zum Zitat Laer S, Mir TS, Behn F et al (2002) Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143:916–922CrossRefPubMed Laer S, Mir TS, Behn F et al (2002) Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143:916–922CrossRefPubMed
12.
Zurück zum Zitat Sugimoto M, Manabe H, Nakau K, Furuya A, Okushima K, Fujiyasu H et al (2010) The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. Circ J 74:998–1005CrossRefPubMed Sugimoto M, Manabe H, Nakau K, Furuya A, Okushima K, Fujiyasu H et al (2010) The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. Circ J 74:998–1005CrossRefPubMed
13.
Zurück zum Zitat Kirk R, Dipchand AI, Rosenthal DN et al (2014) The International Society for Heart and Lung Transplantation guidelines for the management for pediatric heart failure. J Heart Lung Transplant 33:888–909CrossRefPubMed Kirk R, Dipchand AI, Rosenthal DN et al (2014) The International Society for Heart and Lung Transplantation guidelines for the management for pediatric heart failure. J Heart Lung Transplant 33:888–909CrossRefPubMed
14.
Zurück zum Zitat Iacob D, Butnariu A, Leucuţa D, Samaşca G, Deleanu D, Lupan I (2017) Evaluation of NT-proBNP in children with heart failure younger than 3 years old. Rom J Intern Med 55(2):69–74PubMed Iacob D, Butnariu A, Leucuţa D, Samaşca G, Deleanu D, Lupan I (2017) Evaluation of NT-proBNP in children with heart failure younger than 3 years old. Rom J Intern Med 55(2):69–74PubMed
15.
Zurück zum Zitat Ozhan H, Albayrak S, Uzun H, Ordu S, Kaya A, Yazıcı M (2007) Correlation of plasma B-type natriuretic peptide with shunt severity in patients with atrial or ventricular septal defect. Pediatr Cardiol 28(4):272–275CrossRefPubMed Ozhan H, Albayrak S, Uzun H, Ordu S, Kaya A, Yazıcı M (2007) Correlation of plasma B-type natriuretic peptide with shunt severity in patients with atrial or ventricular septal defect. Pediatr Cardiol 28(4):272–275CrossRefPubMed
16.
Zurück zum Zitat Ozyurt A, Baykan A, Argun M, Pamukcu O, Uzum K, Narin F et al (2015) Does N-terminal pro-brain natriuretic peptide correlate with measured shunt fraction in children with septal defects? Cardiol Young 26(3):469–476CrossRefPubMed Ozyurt A, Baykan A, Argun M, Pamukcu O, Uzum K, Narin F et al (2015) Does N-terminal pro-brain natriuretic peptide correlate with measured shunt fraction in children with septal defects? Cardiol Young 26(3):469–476CrossRefPubMed
17.
Zurück zum Zitat Jamei Khosroshahi A, Molaei A, Samadi M, Eskandartash E (2019) The correlation between serum level of brain natriuretic peptide and amount of left to right shunt. J Cardiovasc Thorac Res 11(1):68–71CrossRefPubMedPubMedCentral Jamei Khosroshahi A, Molaei A, Samadi M, Eskandartash E (2019) The correlation between serum level of brain natriuretic peptide and amount of left to right shunt. J Cardiovasc Thorac Res 11(1):68–71CrossRefPubMedPubMedCentral
Metadaten
Titel
N-Terminal Pro-B-Type Natriuretic Peptide as a Marker of Severity of Heart Failure in Children with Congenital Heart Diseases
verfasst von
Ritabrata Roy Chowdhury
Satnam Kaur
Rani Gera
Publikationsdatum
11.08.2023
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 8/2023
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-023-03259-x

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Koronare Herzkrankheit: Das waren die Top-Studien 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Kaffeegenuss sicher bei Vorhofflimmern

Menschen mit Vorhofflimmern fürchten oft, Kaffee könnte schlecht für ihr Herz sein. Solche Ängste sind offenbar unbegründet: Zwei Schweizer Untersuchungen deuten sogar auf eine reduzierte Rate von kardiovaskulären Ereignissen unter Kaffeetrinkern.

Mit jedem Defibrillationsversuch sinkt die Überlebenschance

Wie wirkt es sich auf die Prognose aus, wenn bei Herzstillstand einmal, zweimal oder gar 29 Mal geschockt werden muss? Laut einer aktuellen Studie besteht ein deutlicher Zusammenhang zwischen der Zahl der Defibrillationsversuche und den Überlebenschancen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.